1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Baseline data of 4 cohorts of MND phenotypes and healthy controlsa
PLS (n = 12)ALS-L (n = 12)ALS-B (n = 12)PMA (n = 12)Controls (n= 12)
Male/female7:510:25:711:17:5
Age (yr) (median/range)59.0 (48–74)58.0 (41–78)56.5 (42–72)60.5 (44–72)56.5 (46–80)
Duration symptoms (mo)50.2 ± 24.810.5 ± 2.59.8 ± 3.210.8 ± 2.0NA
Diagnostic delay (mo)24.4 ± 16.06.6 ± 2.56.7 ± 2.76.6 ± 2.9NA
Disease progression rateb0.010 ± 0.0050.027 ± 0.0160.026 ± 0.0180.020 ± 0.010NA
VC (%)91.5 ± 23.3.028101.3 ± 23.898.5 ± 17.9.043102.5 ± 14.9114.6 ± 18.5
ALSFRS-R35.0 ± 4.6<.00140.1 ± 3.9<.00140.1 ± 4.7<.001.41.8 ± 3.7<.00148.0 ± 0
Finger tapping/sc2.3 ± 1.2<.0013.3 ± 1.3.0024.0 ± 1.3.0134.8 ± 0.75.1 ± 0.6
Foot tapping/sc1.4 ± 0.9<.0012.4 ± 1.1.192.9 ± 1.32.4 ± 1.43.4 ± 0.7
NAAx7.46 ± 0.80<.0018.56 ± 1.168.78 ± 1.129.58 ± 0.789.32 ± 0.84
Glx8.06 ± 1.348.75 ± 1.687.99 ± 1.857.68 ± 1.668.42 ± 1.47
mIns4.78 ± 0.80.0244.56 ± 0.944.28 ± 0.814.26 ± 0.913.93 ± 0.74
NAAx/mIns1.62 ± 0.38.0011.97 ± 0.59.0242.12 ± 0.492.35 ± 0.552.46 ± 0.56
  • a Data are given as mean ± SD, unless otherwise indicated. Statistical significance compared with controls was set at P < .05 (P values in superscript).
  • b Disease progression rate = (48 − ALSFRS-R score at baseline) / disease duration (days).
  • c Finger and foot tapping: (L + R) / 2.